David C. Myles - 01 Feb 2023 Form 4 Insider Report for Olema Pharmaceuticals, Inc. (OLMA)

Role
Chief Development Officer
Signature
/s/ John B. Moriarty, Jr., Attorney-in-Fact
Issuer symbol
OLMA
Transactions as of
01 Feb 2023
Transactions value $
$0
Form type
4
Filing time
02 Feb 2023, 16:32:06 UTC
Previous filing
03 Feb 2022
Next filing
21 Sep 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OLMA Stock Option (Right to Buy) Award $0 +150K $0.00 150K 01 Feb 2023 Common Stock 150K $4.87 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the option vest on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.